MedTrace Logo

A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure Chamber

NCT02481856 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2017-01-19

No results posted yet for this study

Summary

The trial is a phase II, randomised, parallel-group, double-blind, placebo-controlled multi-site trial conducted in Canada. Before the start of treatment, the subjects will undergo baseline birch and oak Environmental Exposure Chamber sessions. The treatment duration is 24 weeks. The subjects will undergo birch Environmental Exposure Chamber sessions after 8, 16 and 24 weeks of treatment and an oak Environmental Exposure Chamber session after 24 weeks of treatment.

Conditions

  • Allergic Rhinoconjunctivitis

Interventions

DRUG

SQ tree SLIT-tablet

DRUG

Placebo

Sponsors & Collaborators

  • Inflamax Research Incorporated

    collaborator INDUSTRY

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • Peter Couroux, MD · Inflamax Research Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02481856 on ClinicalTrials.gov